Arvinas (ARVN) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Arvinas (ARVN) over the past year, gaining 11.8% versus a loss of 19.9%. Contineum Therapeutics is the larger company by market cap ($495.8 million vs $484.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | CTNM |
|---|---|---|
| Share price | $7.51 | $13.18 |
| Market cap | $484.55M | $495.85M |
| 1-day change | +0.81% | +3.53% |
| YTD return | -37.18% | +11.37% |
| 1-year return | -19.89% | +11.76% |
| 5-year return | -91.25% | — |
| P/E ratio (TTM) | 28.88 | — |
| EPS (TTM) | $0.26 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $17.79 |
| 52-week low | $6.97 | $8.60 |
| Distance from 52-week high | -48.24% | -25.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +85.49% | +70.18% |
| Average volume | 779.46K | 502.82K |
| Shares outstanding | 64.52M | 32.96M |
| Employees | 246 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed ARVN by 31.7 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ARVN vs CTNM FAQ
Which is bigger, Arvinas or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $495.85M compared with $484.55M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or CTNM?
CTNM returned +11.76% over the past 12 months, compared with -19.89% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.